Clinical Trials in Schwerin, Germany
15 recruiting
Showing 1–19 of 19 trials
Recruiting
Phase 3
A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
Renal Cell Carcinoma
Merck Sharp & Dohme LLC904 enrolled87 locationsNCT07227402
Recruiting
Phase 3
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
Prostate Cancer Metastatic
Merck Sharp & Dohme LLC1,310 enrolled281 locationsNCT06136624
Recruiting
Phase 3
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
Prostate Cancer
AstraZeneca700 enrolled328 locationsNCT06952803
Recruiting
Phase 2
A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer
Breast Cancer
Hoffmann-La Roche60 enrolled25 locationsNCT07054190
Recruiting
Non-interventional Study on Guideline Directed Medical Therapy for Patients With Heart Failure (HF) in Germany
Heart FailureHeart DiseaseCardiovascular Disease+1 more
AstraZeneca438 enrolled6 locationsNCT06675552
Recruiting
Phase 2
A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
Major Depressive Disorder (MDD)Major Depressive Disorder With Anxious Distress
Seaport Therapeutics360 enrolled45 locationsNCT07065240
Recruiting
Phase 3
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
Atrial Fibrillation (AF)
Anthos Therapeutics, Inc.1,900 enrolled721 locationsNCT05712200
Recruiting
Study to Assess Change in Disease Activity of Risankizumab Treatment in Adult Participants With Moderate to Severe Ulcerative Colitis
Ulcerative Colitis
AbbVie200 enrolled55 locationsNCT06764706
Recruiting
Phase 3
A Clinical Study to Improve Brain Function and Quality of Life of Patients With Newly Diagnosed Brain Tumors (Gliomas).
Oligodendroglioma
University Hospital Heidelberg406 enrolled19 locationsNCT05331521
Recruiting
Study of Oral Upadacitinib to Assess Change in Disease Activity in Adult Participants With Ulcerative Colitis
Ulcerative Colitis
AbbVie400 enrolled94 locationsNCT05496348
Recruiting
International HIT-MED Registry (I-HIT-MED)
Childhood Brain Tumor
Universitätsklinikum Hamburg-Eppendorf500 enrolled57 locationsNCT02417324
Recruiting
GMALL Registry and Collection of Biomaterial: Prospective Data Collection Regarding Diagnosis, Treatment and Outcome of Adult Acute Lymphoblastic Leukemia (ALL) Patients and Related Diseases Associated With a Prospective Collection of Biomaterial
Acute Lymphoblastic LeukemiaLeukemiaNon-Hodgkin's Lymphoma
Goethe University10,000 enrolled152 locationsNCT02872987
Recruiting
Phase 1
A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease
Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline130 enrolled32 locationsNCT06154837
Recruiting
Phase 3
Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017
Acute Lymphoblastic Leukemia, Pediatric
Martin Schrappe5,000 enrolled115 locationsNCT03643276
Recruiting
Phase 3
International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma
Lymphoblastic Lymphoma, Childhood
University Hospital Muenster683 enrolled228 locationsNCT04043494
Recruiting
Not Applicable
Dermatitis During Adjuvant Irradiation for BREAst Cancer:
Breast Cancer Female
University Hospital Schleswig-Holstein268 enrolled5 locationsNCT06483477
Recruiting
The Helios Heart Registry: A Standardized Registry for Patients With Specific Cardiac Diseases
Heart FailureAtrial FibrillationCoronary Artery Disease
Helios Health Institute GmbH24,000 enrolled10 locationsNCT04844944
Recruiting
REDUCE LAP-HF III Corvia Protocol 1701
Heart Failure
Corvia Medical500 enrolled27 locationsNCT03191656
Recruiting
Binimetinib Plus Encorafenib Real Life Investigation of Next Generation Melanoma Treatment
Melanoma Stage IVMelanoma Stage III
Pierre Fabre Pharma GmbH750 enrolled59 locationsNCT04045691